Shares of Xencor Inc. (NASDAQ:XNCR) hit a new 52-week high during trading on Monday . The company traded as high as $23.30 and last traded at $23.03, with a volume of 220,118 shares. The stock had previously closed at $22.25.

A number of brokerages recently commented on XNCR. Wedbush reaffirmed an “outperform” rating and issued a $27.00 price target on shares of Xencor in a research note on Tuesday, June 28th. Leerink Swann reissued an “outperform” rating and set a $18.00 price objective on shares of Xencor in a research report on Wednesday, June 29th. Canaccord Genuity reissued a “buy” rating on shares of Xencor in a research report on Tuesday, June 28th. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of Xencor in a research report on Monday, May 2nd. Finally, TheStreet raised Xencor from a “sell” rating to a “hold” rating in a research report on Monday, April 25th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $22.33.

The company has a market capitalization of $892.28 million and a PE ratio of 23.16. The firm’s 50-day moving average is $19.44 and its 200 day moving average is $14.45.

Xencor (NASDAQ:XNCR) last released its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $1.13 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $1.31. The company had revenue of $66 million for the quarter, compared to the consensus estimate of $7.43 million. Analysts anticipate that Xencor Inc. will post $0.72 EPS for the current fiscal year.

In other Xencor news, Director Bruce L. A. Carter sold 3,400 shares of the company’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $22.67, for a total value of $77,078.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $226,700. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Edgardo Baracchini, Jr. sold 2,500 shares of the company’s stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $21.83, for a total value of $54,575.00. Following the completion of the transaction, the insider now directly owns 2,500 shares in the company, valued at approximately $54,575. The disclosure for this sale can be found here.

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.